Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

the mRNA vaccines from Pfizer and Moderna — aren’t effective. Pfizer’s and Moderna’s vaccines were the first to use mRNA technology to induce immunity to a virus, an approach that proved critical in ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

TORONTO — Health Canada has approved Moderna's mRNA vaccine to protect against respiratory syncytial ... manufactured by GSK, ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Pfizer-BioNTech: The Pfizer-BioNTech vaccine ... performing almost as well as the mRNA vaccines in their early trials. The FDA authorized an updated COVID vaccine from Novavax at the end of ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Novavax is approved for children aged 12 and older. Both Moderna and Pfizer-BioNTech vaccines use messenger RNA (mRNA), which ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...